PCM
THRD

Prelude Capital Management’s Third Harmonic Bio THRD Stock Holding History

Prelude Capital Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,822
Closed -$417K – 1384
2025
Q2 		$417K Buy
76,822
+6,922
+10% +$34.5K 0.04% 498
2025
Q1 		$243K Buy
+69,900
New +$339K 0.02% 815
2023
Q4 		– Sell
-16,397
Closed -$105K – 1338
2023
Q3 		$105K Buy
16,397
+555
+4% +$3.39K 0.01% 989
2023
Q2 		$76.2K Buy
+15,842
New +$75.4K 0.01% 951

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prelude Capital Management's THRD Position: Q3 2025 in Review

Prelude Capital Management sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 76,822 shares — an estimated $417K sold.

Prelude Capital Management first reported a position in THRD in Q2 2023 and held it in 4 quarters. The position peaked at $417K in Q2 2025. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Prelude Capital Management reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 76,822 Third Harmonic Bio shares in Q3 2025, an estimated $417K.
  • Prelude Capital Management first reported a position in Third Harmonic Bio in Q2 2023 and held it in 4 quarters.
  • Prelude Capital Management's Third Harmonic Bio position peaked at $417K in Q2 2025.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.